Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Jemperli receives positive funding recommendations from CDA-AMC and INESSS in all adult patients with primary advanced or first recurrent endometrial cancer
GSK is pleased to announce that Jemperli (dostarlimab for injection) has received positive reimbursement recommendations
-
GSK and Dalhousie University Collaborate to Address Health Equity Gaps through the GSK Vaccinology and Health Equity Fellowship Award
Dr. Stephana Julia Moss, an investigator at the Canadian Center for Vaccinology (CCfV), Dalhousie University, has been honoured as
-
New real-world study reveals oral corticosteroid overuse in patients with chronic rhinosinusitis with nasal polyps
A new Canadian real-world study, ACTIONS
-
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC)
-
GSK’s depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab
-
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit for these patients
GSK today announced that Health Canada has approved Jemperli (dostarlimab for injection) in combination with chemotherapy
-
GSK’s Nucala (mepolizumab) accepted for review by Health Canada for the treatment of COPD
GSK has submitted a Supplementary New Drug Submission (SNDS) to Health Canada
-
National survey reveals low understanding of shingles risk factors and lack of concern among those at increased risk
A new national survey of Canadian adults reveals significant gaps in understanding of shingles risk factors.
-
Canada’s Drug Agency recommends OJJAARA for public reimbursement
Ojjaara (momelotinib) has received a reimburse with conditions recommendation from Canada’s Drug Agency (CDA-AMC).
-
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer
GSK announced today that Nova Scotia has become the first province to publicly reimburse Jemperli (dostarlimab for injection)
-
In honour of World COPD Day GSK promotes environmentally responsible disposal of used inhalers through health product stewardship program
To mark World Chronic Obstructive Pulmonary Disease (COPD) Day, GSK Canada is placing a spotlight on its partnership with HPSA
-
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms
-
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
GSK’s AREXVY has been approved in Canada for the prevention of lower respiratory tract disease (LRTD).
-
GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for JEMPERLI for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
GSK is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Jemperli
-
Data from new national study exposes oral corticosteroids overuse in Canadian patients with severe asthma
The ALERT study on uncontrolled severe asthma in Canada was recently presented at CHEST and at the ERS congress, showcasing real-world data
-
New survey reveals widespread lack of awareness about Respiratory Syncytial Virus (RSV) among older Canadians, despite health risks for this population
With healthy ageing becoming a topic of interest in Canada, new survey data highlighted gaps in knowledge among older Canadians.
-
Health Canada grants full approval to Jemperli for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
GSK today announced that Health Canada granted full approval for Jemperli (dostarlimab for injection)
-
Quebec’s Committee on Immunization (CIQ) recommends use of RSV vaccines, including AREXVY, for older adult populations at risk of severe outcomes
The Committee on Immunization of Quebec (Comité sur l’immunisation du Québec - CIQ) has recommended use of RSV
-
National Advisory Committee on Immunization (NACI) recommends RSV vaccines, including AREXVY, for older adult populations
The National Advisory Committee on Immunization (NACI) has strongly recommended RSV (respiratory syncytial virus) vaccines, including AREXVY
-
JEMPERLI receives recommendation from Canada’s Drug Agency for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer
Jemperli (dostarlimab for injection) has received a reimburse with conditions recommendation from Canada’s Drug Agency (CDA-AMC)
